| Trial ID: | L5821 |
| Source ID: | NCT00351585
|
| Associated Drug: |
Vildagliptin
|
| Title: |
A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Vildagliptin
|
| Outcome Measures: |
Primary: Change from baseline in maximal insulin secretory capacity at 12 weeks|Durability of this effect after a 2-week washout | Secondary: Change from baseline in beta-cell sensitivity to glucose at 12 weeks|Durability of this effect after a 2-week washout|Chance from baseline in glucagon secretion at 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
39
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-07
|
| Completion Date: |
2005-09
|
| Results First Posted: |
|
| Last Update Posted: |
2012-05-07
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00351585
|
